Article thumbnail
Location of Repository

Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant Tuberculosis

By Sarah L. Kinnings, Nina Liu, Nancy Buchmeier, Peter J. Tonge, Lei Xie and Philip E. Bourne

Abstract

The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis around the world, including in industrialized nations, poses a great threat to human health and defines a need to develop new, effective and inexpensive anti-tubercular agents. Previously we developed a chemical systems biology approach to identify off-targets of major pharmaceuticals on a proteome-wide scale. In this paper we further demonstrate the value of this approach through the discovery that existing commercially available drugs, prescribed for the treatment of Parkinson's disease, have the potential to treat MDR and XDR tuberculosis. These drugs, entacapone and tolcapone, are predicted to bind to the enzyme InhA and directly inhibit substrate binding. The prediction is validated by in vitro and InhA kinetic assays using tablets of Comtan, whose active component is entacapone. The minimal inhibition concentration (MIC99) of entacapone for Mycobacterium tuberculosis (M.tuberculosis) is approximately 260.0 µM, well below the toxicity concentration determined by an in vitro cytotoxicity model using a human neuroblastoma cell line. Moreover, kinetic assays indicate that Comtan inhibits InhA activity by 47.0% at an entacapone concentration of approximately 80 µM. Thus the active component in Comtan represents a promising lead compound for developing a new class of anti-tubercular therapeutics with excellent safety profiles. More generally, the protocol described in this paper can be included in a drug discovery pipeline in an effort to discover novel drug leads with desired safety profiles, and therefore accelerate the development of new drugs

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2699117
Provided by: PubMed Central

Suggested articles

Citations

  1. (1995). A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson’s disease.
  2. (2007). A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites.
  3. (2009). A unified statistical model to support local sequence order independent similarity searching for ligand binding sites and its application to genome-based drug discovery.
  4. (2008). An improved relaxed complex scheme for receptor flexibility in computer-aided drug design.
  5. (2003). Association of mycothiol with protection of Mycobacterium tuberculosis from toxic oxidants and antibiotics.
  6. (2008). Compound cytotoxicity profiling using quantitative high-throughput screening. Environ Health Perspect 116: 284–291. Chemical Genomics Approach to Drug Repurposing PLoS
  7. (1999). Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate.
  8. (2008). Detecting evolutionary relationships across existing fold space, using sequence order-independent profile–profile alignments.
  9. (2002). Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI).
  10. (2008). Discovery of drug-like inhibitors of an essential RNA-editing ligase in Trypanosoma brucei.
  11. (2009). Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors.
  12. (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration.
  13. (2007). eHiTS: A new fast, exhaustive flexible ligand docking system.
  14. (2006). Encyclopedia of Pharmaceutical Technology: Informa HealthCare.
  15. (2007). Enoyl reductases as targets for the development of anti-tubercular and anti-malarial agents.
  16. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.
  17. (2005). Finding new tricks for old drugs: an efficient route for public-sector drug discovery.
  18. (2007). From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis.
  19. (1997). Gapped BLAST and PSI-BLAST: a new generation of protein database search programs.
  20. (2006). Global mapping of pharmacological space.
  21. (2006). High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis.
  22. (2006). Hudson A
  23. (2007). In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators.
  24. (2003). Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK.
  25. (1994). inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis.
  26. (2008). Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
  27. (2007). Mechanism of thioamide drug action against tuberculosis and leprosy.
  28. (2007). Multi-target therapeutics: when the whole is greater than the sum of the parts.
  29. (2008). Network pharmacology: the next paradigm in drug discovery.
  30. (2006). Ortiz de Montellano PR
  31. (2005). Pathway to synthesis and processing of mycolic acids in Mycobacterium tuberculosis.
  32. (2003). Poso A
  33. (2007). R: A Language and Environment for Statistical Computing.
  34. (2004). Selective optimization of side activities: another way for drug discovery.
  35. (2006). Selective optimization of side activities: the SOSA approach.
  36. (2003). Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosis.
  37. (2007). Surflex-Dock 2.1: robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search.
  38. (2003). Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data.
  39. (2003). The isoniazid-NAD adduct is a slow, tightbinding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance.
  40. (2000). The Protein Data Bank.
  41. (2005). The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema.
  42. (2003). Tolcapone-related liver dysfunction: implications for use in Parkinson’s disease therapy.
  43. (2005). Tolcapone: a review of its use in the management of Parkinson’s disease.
  44. (2006). Tuberculosis Fact sheet Nu104 - Global and regional incidence.
  45. (2004). Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition.
  46. (2005). ZINC–a free database of commercially available compounds for virtual screening.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.